Galectin Therapeutics Q3 2026 Net Loss Applicable to Common Stockholders Narrows 56% to $3.6 Million Versus Quarter Ended June 30, 2025

By Public Technologies
  • Galectin Therapeutics’ Q3 2026 net loss applicable to common stockholders narrowed 56% to $3.6 million versus the quarter ended June 30, 2025.
  • Research and development expenses fell 38% year over year to $1.6 million, primarily due to timing of NAVIGATE clinical trial expenditures.
  • A July 31, 2026, debt-to-equity conversion eliminated approximately $105.8 million in principal and accrued interest under five credit facilities.
  • Cash totaled $11.7 million at September 30, 2026; management expects sufficient funding for planned operations through June 2027.
  • The registrational Phase 3 belapectin protocol was submitted to FDA in Q3 2026 following alignment on key trial-design elements.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galectin Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-26-043989), on November 16, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.